Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;141(12):2131-8.
doi: 10.1007/s00432-015-1983-5. Epub 2015 May 13.

Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011

Melissa A Deadmond  1   2 , Julie A Smith-Gagen  3   4
Affiliations

Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011

Melissa A Deadmond et al. J Cancer Res Clin Oncol. 2015 Dec.

Abstract

Purpose: Recent diagnostic and cancer reporting changes influencing myeloproliferative neoplasms (MPNs) encourage the assessment of trends and examination of the recently identified MPN subtypes: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), across the age continuum by race and ethnicity.

Methods: Surveillance, Epidemiology, and End Results data provided MPN incidence data since 1973 and MPN subtype data since 2001. Joinpoint regression estimated annual percent changes. Poisson regression estimated risk ratios.

Results: The 2005 JAK2 V617F discovery and the 2008 WHO diagnostic guideline for the JAK2 V617F mutation coincide with a 31 % increase in ET and a 21 % decrease in PV incidence rates. We found that younger women had a 13-33 % higher ET risk and that women under the age of 34 had a 58 % higher PMF risk, relative to men. Blacks, aged 35-49 with a higher ET risk, also had a 69 % higher PMF risk relative to whites.

Conclusion: Demographic characteristic of ET and PMF patients may be useful for improving risk prediction and informing clinical screening and treatment strategies. Changing guidelines, new discoveries, and in-depth analysis of a large population-based study have implications for accurately identifying incident cases of MPNs, MPN subgroups, and health resource planning.

Keywords: Essential thrombocythemia; Incidence; Myeloproliferative neoplasm; Polycythemia vera; Primary myelofibrosis; Trends.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Trends of MPN incidence rates, annual percent change (APC). a Total and by gender, SEER 1973–2010, November 2013 submission; b by race, SEER 1973–2010, November 2013 submission; c by age group, SEER 1973–2010, November 2013 submission
See this image and copyright information in PMC

References

    1. Alvarez-Larrán BB, Pereira A, Kerguelen A, Hernández-Boluda JC, Martínez-Avilés L et al (2014) JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 89:517–523 - PubMed
    1. Anderson LA, McMullin MF (2014) Epidemiology of MPN: what do we know. Curr Hematol Malig Rep 9:340–349 - PubMed
    1. Bain BJ (2004) The World Health Organization classification of myeloproliferative and myelodysplastic syndromes. Curr Diagn Pathol 10:394–403
    1. Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R (2009) The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer 9:252 - PMC - PubMed
    1. Chasseriau J, Rivet J, Bilan F, Chomel J-C, Guilhot F, Bourmeyster N, Kitzis A (2004) Characterization of the different BCR–ABL transcripts with a single multiplex RT-PCR. J Mol Diagn 6:343–347 - PMC - PubMed

MeSH terms

LinkOut - more resources